April 2026 in “International Journal of Clinical Case Reports and Reviews” A new non-invasive laser system improves chronic disease management and metabolic health.
May 2021 in “Journal of the American College of Cardiology” An 11-year-old girl with Kawasaki disease experienced hair loss that improved after treatment.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
2 citations
,
February 2023 in “Transgenic Research” The E2 protein affects gene activity in hair follicles of mice.
December 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
June 2020 in “Zenodo (CERN European Organization for Nuclear Research)”
33 citations
,
November 2014 in “Military Medicine” The U.S. military's teledermatology program was effective in providing fast and successful skin care in remote locations, preventing unnecessary evacuations.
84 citations
,
December 2018 in “Genetics in Medicine” Pegvaliase is recommended for treating adults with phenylketonuria.
28 citations
,
February 2014 in “Journal of Telemedicine and Telecare” Smartphone-based teledermatology is effective for diagnosing skin diseases in the military with good accuracy.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
April 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TET enzymes are important for skin and hair development by controlling gene activity in specific areas.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
November 2025 in “Discover Food” Catechins-rich tea extract may help reduce hair loss and promote hair growth.
April 2018 in “Journal of Investigative Dermatology” Mint water extract boosts protective enzymes in skin cells.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
198 citations
,
May 2021 in “Advanced Materials” Triboelectric nanogenerators can use body movement to power therapeutic treatments, potentially transforming personalized healthcare.
3 citations
,
October 2024 in “Animals” An allele of the KRTAP13-2 gene may improve wool quality in sheep.
25 citations
,
July 2015 in “EMBO Reports” Tmem50b and 2610305D13Rik genes play key roles in early mouse embryo development.
88 citations
,
May 2024 in “Journal of Extracellular Vesicles” Extracellular vesicles show promise as treatments but need more research for safety and effectiveness.
2 citations
,
January 1989 Tay syndrome is a unique genetic disorder causing skin, hair, and developmental issues.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
July 2025 in “Current Issues in Molecular Biology” Bio-Pulsed sEVs improve hair growth and skin rejuvenation.
September 2023 in “Journal of the American Academy of Dermatology”
Combining PRP with Tressfix Serum is more effective for hair regrowth in telogen effluvium than using either alone.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.